Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians

T Cell, Antibody and Cytokine Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04706143

Enrollment

100

Registered

2021-01-12

Start date

2021-01-15

Completion date

2021-08-01

Last updated

2021-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Vaccines

Keywords

COVID-19, Safety, Efficacy, T cell responses, Cytokine responses, Antibody responses

Brief summary

The recent Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and development of safe, effective vaccines is mandatory to return back to pre pandemic life. Many vaccines have been developed and requested by the authorities after the emergency license issued. The main mechanism of protection is through humoral and cell-mediated immune responses that might reduce the potential for disease development or severity. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection. Preliminary data are now available indicating safty and effecacy of different vaccines . The vaccines were tolerated, with induction of neutralizing antibodies and antigen-specific T cells against the SARS-CoV-2 spike protein. The aim of this work is to evaluate the immune responses in adults, aged 25-65 years, up to 8 weeks after vaccination with a single and double doses live inactivated (Sinopharm), mRNA (Pfizer/ Biontech) and viral vector (Oxford/AZ- ChAdOx1 nCoV-19) vaccines. The Th1- response ( interferon-γ and tumor necrosis factor-α cytokine secretion by CD4+ T cells) and antibody production predominantly of IgG1 and IgG3 subclasses as well as CD8+ T cells mono, polyfunctional and cytotoxic phenotypes, will be also measured.

Interventions

BIOLOGICALCOVID-19 Vaccines

different available vaccines: live inactivated, mRNA and viral vector vaccines

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy adults receiving COVID-19 vaccines

Exclusion criteria

* any contraindication of each COVID-19 vaccine as listed by WHO

Design outcomes

Primary

Measure	Time frame	Description
measure immune cell activation induced by the vaccine	8 weeks	estimate number of lymphocytes, T cells, Natural killer cells and B cells
measure antibody response to vaccines	8 weeks	evaluation of IgG and IgM levels, mg/dl
measure the cytokine response to different vaccines	8 weeks	level of IL-1, IL-2, TNF-alpha, IFN- gamma, My/dl

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026